In his weekly clinical update, Dr. Griffin discusses how vaccination and vaccine hesitancy affects public health and disease spread in terms of mpox, the first human death from H5N1 in US, why one should not feed their pets raw pet food and the metapneumonia outbreak in China before reviewing the recent statistics on RSV, influenza and SARS-CoV-2 infections, the WasterwaterScan dashboard, where to find PEMGARDA, how nirmatrelvir-ritonavir/Paxlovid reduces adverse outcomes of COVID in patients with kidney disease, provides information for Columbia University Irving Medical Center’s long COVID treatment center, SARS-CoV-2 infection affects skin conditions including shingles and if long antiviral treatment affects long COVID.
Click arrow to play
Download TWiV 1182 (19 MB .mp3, 31 min)
Subscribe (free): Apple Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Mpox vaccination hesitancy, previous immunisation coverage, and vaccination readiness in the African region (eClincial Medicine)
- Global prevalence and correlates of mpox vaccine acceptance and uptake (Communications Medicine)
- First case of new mpox variant in France (Reuters)
- First “Bird flu” death in US (NY Times)
- Emerging threat of H5N1 to human health (NEJM)
- Don’t feed your pets raw food (County of Los Angeles Public Health)
- Oregon, nationwide raw pet food recall (CIRAP)
- Raw cat food avian flu, is this like raw milk? (CIDRAP)
- Human metapneumovirus surging in China (The Guardian)
- Viral video of viral chaos: human metapneumovirus in Chinese hospital (The Economic Times)
- Human metapneumovirus in China (NY Times)
- Acute respiratory infections including human metapneumovirus in northern hemisphere (WHO)
- Waste water scan for 11 pathogens (WastewaterSCan)
- US respiratory virus activity (CDC Respiratory Illnesses)
- Weekly surveillance report: clift notes (CDC FluView)
- RSV: Waste water scan for 11 pathogens (WastewaterSCan)
- RSV-Network (CDC Respiratory Syncytial virus Infection)
- US respiratory virus activity (CDC Respiratory Illnesses)
- Waste water scan for 11 pathogens (WastewaterSCan)
- COVID-19 deaths (CDC)
- COVID-19 national and regional trends (CDC)
- COVID-19 variant tracker (CDC)
- SARS-CoV-2 genomes galore (Nextstrain)
- Where to get pemgarda (Pemgarda)
- EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)
- Fusion center near you….if in NY (Prime Fusions)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Infectious Disease Society guidelines for treatment and management (ID Society)
- Drug interaction checker (University of Liverpool)
- The effect of nirmatrelvir-ritonavir on short- and long-term adverse outcomes from COVID-19 among patients with kidney disease (OFID)
- Paxlovid tied to lower risk of hospital stay, heart problems, death in adults with kidney disease and COVID (CIDRAP)
- Molnupiravir safety and efficacy (JMV)
- Convalescent plasma recommendation for immunocompromised (ID Society)
- What to do when sick with a respiratory virus (CDC)
- When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)
- Managing healthcare staffing shortages (CDC)
- Steroids, dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Daniel Griffin’s evidence based medical practices for long COVID (OFID)
- Long COVID hotline (Columbia : Columbia University Irving Medical Center)
- Chronic urticaria, vitiligo, alopecia areata, and herpes zoster following COVID-19 infection (Journal of Dermatology)
- Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID:
- (Communications Medicine)
- Letters read on TWiV 1182
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1182: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.
@John writes. True.
Like your sources! Share mine:
His latest opinion on the risk assesments, quote:
Fouchier questioned whether the government’s current effort to weight the benefits and risks of this kind of research is going to provide any new insights that haven’t already been discussed over the last three years since the debate over his experiments first began. “I think that the quantitative risk and benefit analysis is going to be close to impossible,” Fouchier told NPR. “Whatever the numbers are they come up with, in the end it will still be a judgment call by someone, somewhere.”.
http://www.npr.org/blogs/health/2014/12/18/371686933/nih-allows-restart-of-mers-research-that-was-deemed-too-risky
To deal with all uncertainties in a scientific way this should show up as a large error margin.
http://www.saburchill.com/IBbiology/sci_invest/007.html
Lipsitch & Inglesby: There is no rigorous, objective, credible risk assessment process to judge the risks and benefits of proceeding with it. We believe that the responsible course is to take a research pause until such a risk assessment process is established, which creates a stronger basis for decisions and actions.
http://mbio.asm.org/content/5/6/e02366-14.full
The European Commission is also evaluating the risks of synthetic biology again, contributions still welcome:
http://ec.europa.eu/health/scientific_committees/consultations/public_consultations/scenihr_consultation_26_en.htm
Throws down the gauntlet, states: Flu experiments cause 2,000 to 1,400,000 deaths per year.
http://www.forbes.com/sites/stevensalzberg/2015/01/12/flu-experiments-may-cause-2000-deaths-per-year/